Yi Jin1, Shanshan Lu1, You Lin1, Xiaoyue Mou2. 1. Department of Ophthalmology, First People's Hospital of Taizhou, Taizhou, China. 2. Department of Rheumatology, First People's Hospital of Taizhou, No. 218 Hengjie Road, Taizhou, 318020, China. yue83673907@163.com.
Abstract
BACKGROUND: Tumor necrosis factor inhibitor (TNFi) is recently reported to treat noninfectious uveitis (NIU) effectively. However, as a new kind of TNFi, golimumab is just on the market in China for several years, and its administration for NIU treatment lacks sufficient evidence. Therefore, the current study aimed to investigate the efficacy and safety of golimumab in refractory NIU patients. METHODS: Thirty NIU patients with 49 affected eyes refractory to conventional treatments (corticosteroids and immunosuppressive agents) were consecutively enrolled. They received treatment of TNFi (50 mg golimumab every 4 weeks) for at least 6 months. The anterior chamber cell grade, vitreous haziness grade, central macular thickness, and visual acuity were evaluated at baseline, month (M) 1, M3, and M6. RESULTS: After treatment, the anterior chamber cell grade declined from baseline (0.6 ± 0.7) to M6 (0.3 ± 0.5) (P < 0.001); the vitreous haziness grade decreased from baseline (1.2 ± 1.2) to M6 (0.4 ± 0.5) (P < 0.001); meanwhile, the central macular thickness also reduced from baseline (351.4 ± 90.8 μm) to M6 (271.8 ± 54.4 μm) (P < 0.001). In terms of visual acuity (LogMAR), it showed a declined trend from baseline (0.5 ± 0.3) to M6 (0.4 ± 0.2), but without statistical significance (P = 0.096). Subgroup analyses revealed that TNFi history related to decreased golimumab efficacy. In addition, 13.3% of patients had adverse events, including elevated liver enzymes (6.7%), fatigue (3.3%), and rash (3.3%). CONCLUSION: Golimumab is effective and safe for refractory NIU treatment, while a large-scale trial is still needed for verification.
BACKGROUND: Tumor necrosis factor inhibitor (TNFi) is recently reported to treat noninfectious uveitis (NIU) effectively. However, as a new kind of TNFi, golimumab is just on the market in China for several years, and its administration for NIU treatment lacks sufficient evidence. Therefore, the current study aimed to investigate the efficacy and safety of golimumab in refractory NIU patients. METHODS: Thirty NIU patients with 49 affected eyes refractory to conventional treatments (corticosteroids and immunosuppressive agents) were consecutively enrolled. They received treatment of TNFi (50 mg golimumab every 4 weeks) for at least 6 months. The anterior chamber cell grade, vitreous haziness grade, central macular thickness, and visual acuity were evaluated at baseline, month (M) 1, M3, and M6. RESULTS: After treatment, the anterior chamber cell grade declined from baseline (0.6 ± 0.7) to M6 (0.3 ± 0.5) (P < 0.001); the vitreous haziness grade decreased from baseline (1.2 ± 1.2) to M6 (0.4 ± 0.5) (P < 0.001); meanwhile, the central macular thickness also reduced from baseline (351.4 ± 90.8 μm) to M6 (271.8 ± 54.4 μm) (P < 0.001). In terms of visual acuity (LogMAR), it showed a declined trend from baseline (0.5 ± 0.3) to M6 (0.4 ± 0.2), but without statistical significance (P = 0.096). Subgroup analyses revealed that TNFi history related to decreased golimumab efficacy. In addition, 13.3% of patients had adverse events, including elevated liver enzymes (6.7%), fatigue (3.3%), and rash (3.3%). CONCLUSION: Golimumab is effective and safe for refractory NIU treatment, while a large-scale trial is still needed for verification.
Authors: Jeffrey R Curtis; Soumya D Chakravarty; Shawn Black; Shelly Kafka; Stephen Xu; Wayne Langholff; Dennis Parenti; Andrew Greenspan; Sergio Schwartzman Journal: Rheumatol Ther Date: 2021-08-20
Authors: Mihika B Dave; Alpa J Dherai; Devendra C Desai; Bhamini G Keny; Dhanashri N Shetty; Satish Kulkarni; Kiran Peddy; Tester F Ashavaid Journal: Indian J Gastroenterol Date: 2020-10-29
Authors: Miguel Cordero-Coma; Vanesa Calvo-Río; Alfredo Adán; Ricardo Blanco; Carolina Álvarez-Castro; Marina Mesquida; Sara Calleja; Miguel A González-Gay; José G Ruíz de Morales Journal: Mediators Inflamm Date: 2014-05-28 Impact factor: 4.711